620
Participants
Start Date
May 14, 2018
Primary Completion Date
October 21, 2019
Study Completion Date
January 8, 2020
FE 999302 (1 μg) and follitropin delta
Daily dose of 1 μg of FE 999302, a recombinant human chorionic gonadotropin (rhCG) solution for subcutaneous injection; individualized follitropin delta dose.
FE 999302 (2 μg) and follitropin delta
Daily dose of 2 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
FE 999302 (4 μg) and follitropin delta
Daily dose of 4 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
FE 999302 (8 μg) and follitropin delta
Daily dose of 8 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
FE 999302 (12 μg) and follitropin delta
Daily dose of 12 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
Placebo and follitropin delta
Daily dose of placebo; individualized follitropin delta dose.
Universitair Ziekenhuis Gent (UZ Gent), Ghent
Universitair Ziekenhuis Brussel, Jette
Institut fur Reproduktionsmedizin und Genetik, Karlovy Vary
Fertimed, Olomouc
GYNEM, Prague
IVF CUBE, Prague
Aalborg University Hospital, Aalborg
Rigshospitalet, Copenhagen
Dansk Fertilitetsklinik, Frederiksberg
Hvidovre Hospital, Hvidovre
Dexeus Woman's Health, Barcelona
Instituto Valenciano de Infertilidad (IVI) - Bilbao, Leioa
GINEFIV - Clinica Belen Location, Madrid
Instituto Valenciano de Infertilidad (IVI) - Madrid, Madrid
Instituto Valenciano de Infertilidad (IVI) - Sevilla, Seville
Instituto Valenciano de Infertilidad (IVI) - Valencia, Valencia
Glasgow Royal Infirmary, Glasgow
Liverpool Women's Hospital, Liverpool
Guy's and St Thomas' NHS Trust, London
Kings College (Assisted Conception Unit), London
Lead Sponsor
Ferring Pharmaceuticals
INDUSTRY